The purchase adds Surgimend and Primatrix, both acellular biologic matrices, to Integra’s portfolio of products; and also adds regenerative technology-based products and a new base of sales in attractive adjacent markets, specifically abdominal wall repair and plastic and reconstructive surgery. The acquisition is also hoped to expand the company’s sales force to support market demand and drive sales growth in operation rooms, burn centers, and wound care clinics with the addition of about 125 sales representatives and managers in the United States.
“We are enthusiastic about the strategic fit of these two organizations, and the positive impact TEI has on both top and bottom-line metrics,” stated Peter Arduini, Integra’s president and CEO. “With this acquisition, we have a significant opportunity to build our platform and fuel a robust pipeline of regenerative products to accelerate Integra’s overall growth.”
“The combined organization will offer surgeons a leading regenerative technology platform for indications in soft tissue reconstruction and wound repair,” said Mark Augusti, Integra’s corporate vice president and president, Orthopedics and Tissue Technologies. “In addition to TEI’s complementary call points in the wound care clinic and operating room, TEI’s products provide surgeons with different strength and handling characteristics.”
Integra makes devices in the specialty surgical solutions, orthopedics and tissue technologies spaces.